Completed PHASE3 INTERVENTIONAL 2-arm NCT01544595

Extension Study of Secukinumab Prefilled Syringes in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

A Multicenter, Double-blind, Randomized Withdrawal Extension Study of Subcutaneous Secukinumab in Prefilled Syringes to Demonstrate Long-term Efficacy, Safety, and Tolerability up to 4 Years in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis Completing Preceding Psoriasis Phase III Studies With Secukinumab

Sponsor: Novartis Pharmaceuticals

Conditions Moderate to Severe Plaque-type Psoriasis

Interventions Placebo Secukinumab (AIN457)

Updated 12 times since 2017 Last updated: Nov 27, 2018 Started: Jun 19, 2012 Primary completion: Jun 26, 2017 Completion: Jun 26, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Moderate to Severe Plaque-type Psoriasis and is currently completed. Novartis Pharmaceuticals leads this study, which shows 12 recorded versions since 2012 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

12 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jan 2019 — Jan 2021 [monthly]

Completed PHASE3

▶ Show 7 earlier versions

Jun 2018 — Jan 2019 [monthly]

Completed PHASE3
May 2018 — Jun 2018 [monthly]

Completed PHASE3
Apr 2018 — May 2018 [monthly]

Completed PHASE3
Dec 2017 — Apr 2018 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
May 2017 — Dec 2017 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — May 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Jun 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis Pharmaceuticals

Data source: Novartis

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Ann Arbor, United States , Asahikawa, Japan , Augsburg, Germany , Austin, United States , Barcelona, Spain , Barranquilla, Colombia , Berlin, Germany , Bielefeld, Germany , Birmingham, United States and 145 more locations